Bufexamac
Anton C. de Groot in Monographs in Contact Allergy, 2021
In a period of 1.5 year in 1991-1992, at a University clinic in Germany, 4 patients (3 women, 1 man, ages 28,29,34, and 62 years) were investigated who had developed an erythema multiforme-like reaction with urticarial papules and plaques following acute contact dermatitis from 2 different bufexamac-containing topical preparations. Bufexamac had been applied to discrete erythema (n=3) or circumscribed atopic dermatitis, and allergic contact dermatitis appeared after a few days to 3 weeks. Histologically, the lesions did not show changes typical of erythema multiforme. Patch tests were positive to bufexamac 5% in all 4, to 1% pet. in 2 and all 4 also reacted to their own bufexamac ointment/cream. The authors suggest that a systemic allergic reaction with spreading of the lesions may have occurred from percutaneous absorption of the allergen (26).
Diagnostic Approach to Rash and Fever in the Critical Care Unit
Cheston B. Cunha, Burke A. Cunha in Infectious Diseases and Antimicrobial Stewardship in Critical Care Medicine, 2020
Erythema multiforme may present with varying degrees of severity (previously classified as EM minor and major) [10]. Bullae and systemic symptoms are absent in less severe EM. The rash rarely affects the mucous membranes and is usually limited to the extensor surfaces of the extremities. This mild form of EM is often associated with HSV infection. Conversely, drug reactions are usually associated with more severe manifestations of EM. Erythema multiforme can be further classified into EM with mucosal involvement and EM without mucosal involvement and is further subdivided into EM minus (<1 mucosal site) and EM majus (>2 mucosal sites) [100]. Fever, cheilosis, stomatitis, balanitis, vulvitis, and conjunctivitis can also occur [95]. Diagnosis of EM is based on clinical findings. Histopathological analysis can help to differentiate EM from other mucocutaneous diseases, including pemphigus vulgaris, paraneoplastic pemphigus, mucosal bullous pemphigoid, linear IgA dermatosis, hand-foot-mouth disease, erosive lichen planus, fixed drug eruption, lupus erythematosus, and cutaneous vasculitis [100].
Thalidomide
Sarah H. Wakelin, Howard I. Maibach, Clive B. Archer in Handbook of Systemic Drug Treatment in Dermatology, 2015
Thalidomide is only licensed in Europe for the treatment of multiple myeloma. It is widely used to treat leprosy reactions (erythema nodosum leprosum) and licensed for this indication in the USA. It has also been reported to be of benefit in a range of inflammatory skin diseases including: Actinic prurigo.Cutaneous lupus erythematosus.Erythema nodosom leprosum.Nodular prurigo.Pyoderma gangrenosum.Severe apthous stomatitis and Behçet’s syndrome.Graft-versus-host disease.Cutaneous sarcoidosis.Erythema multiforme.Kaposi’s sarcoma.Lichen planus.Uraemic pruritus.Systemic mastocytosis.
Erythema multiforme following exposure to the herbicide atrazine
Published in Baylor University Medical Center Proceedings, 2021
Madeline Frizzell, Nhan M. Nguyen, Sonal A. Parikh, Maya Sinai, Leonard Goldberg
Erythema multiforme is an acute, self-limiting, inflammatory skin eruption with many known causes, most commonly infectious agents and drugs. Less common causes include malignancy, environmental factors, autoimmune disease, and vaccinations.1 There have been a few reports of erythema multiforme resulting from exposure to the herbicides paraquat, glycophosphate, alachlor, and butachlor, but no reports discussing an erythema multiforme reaction to the herbicide atrazine.2–5 We present a case of erythema multiforme caused by atrazine, or 1-chloro-3-ethylamino-5-isopropylamino-2,4,6-triazine.
Cushings syndrome complicating pemphigoid gestationis
Published in Cogent Medicine, 2018
O.Y. Olisova, N.P. Tepljuk, A.R. Hubail, R.K. Belkharoeva, O.V. Grabovskaya, V.B. Pinegin
In the beginning of March 2017, the time when she presented to our practice, the differential diagnosis we had in mind was bullous pemphigoid, Duhring dermatitis, and erythema multiform. Based on the clinical presentation, as well as on results of the histologic examination and of the indirect immunofluorescence test (IIFT) the patient was given the diagnosis of erythema multiforme. She was administered Dapson 100 mg a day and Prednisolone was reduced by 5 mg a week. The patient was hospitalized for further examination and management.
Erythema multiforme after third COVID-19 vaccination (Pfizer-BioNTech)
Published in Baylor University Medical Center Proceedings, 2022
Sonali Batta, Austinn C. Miller, Susuana Adjei, Laurie A. Temiz, Stephen K. Tyring
Erythema multiforme (EM) may occur in the setting of recent COVID-19 infection or vaccination. Timely recognition and treatment are necessary to exclude other potential causes of EM and prevent worsening of skin and mucous membrane involvement.
Related Knowledge Centers
- Immune Complex
- Immunoglobulin M
- Microcirculation
- Oral Mucosa
- Target Lesion
- Erythema
- Skin Condition
- Erythema Multiforme Minor
- Erythema Multiforme Major
- Total Body Surface Area